← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,612	-96	-4%	$164B
2	2 Danaher DHR $158B	2,184	-130	-6%	$108B
3	3 Novartis NVS $279B	1,604	+89	+6%	$22B
4	4 Regeneron Pharmaceuticals REGN $80.1B	1,400	+10	+0.7%	$69.8B
5	5 Agilent Technologies A $49.1B	1,075	-74	-6%	$28.9B
6	6 Illumina ILMN $41B	850	-12	-1%	$19.3B
7	7 Alnylam Pharmaceuticals ALNY $30B	793	-58	-7%	$43.4B
8	8 Charles River Laboratories CRL $14.4B	560	-23	-4%	$9.86B
9	9 Revvity RVTY $17B	503	-9	-2%	$10.1B
10	10 Ionis Pharmaceuticals IONS $7.1B	497	+4	+0.8%	$13B
11	11 CRISPR Therapeutics CRSP $4.86B	492	+12	+3%	$3.67B
12	12 Guardant Health GH $21.9B	486	-11	-2%	$12.5B
13	13 BridgeBio Pharma BBIO $12.7B	462	+27	+6%	$14.4B
14	14 Arrowhead Research ARWR $8.25B	438	+37	+9%	$7.58B
15	15 Krystal Biotech KRYS $9.79B	368	+34	+10%	$7.32B
16	16 GRAIL Inc GRAL $6.24B	366	-59	-14%	$1.82B
17	17 PTC Therapeutics PTCT $4.98B	352	-1	-0.3%	$6.51B
18	18 Qiagen QGEN $9.41B	346	+24	+7%	$5.02B
19	19 Bruker BRKR $8.47B	345	-10	-3%	$4.94B
20	20 Sarepta Therapeutics SRPT $1.78B	345	-2	-0.6%	$2.24B
21	21 Veracyte VCYT $3.5B	334	+5	+2%	$2.84B
22	22 10x Genomics TXG $9.52B	332	+9	+3%	$2.66B
23	23 Intellia Therapeutics NTLA $1.6B	304	+11	+4%	$1.41B
24	24 Adaptive Biotechnologies ADPT $4.09B	298	+15	+5%	$2.11B
25	25 Ultragenyx Pharmaceutical RARE $1.47B	298	+10	+3%	$2.05B